Novartis | NVS - Operating Expenses


Novartis reported $9.8B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bausch Health Companies USD 2.04B 42M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.8B 23M Dec/2025
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Sanofi EUR 10.71B 1.32B Dec/2025
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026